Wide tissue distribution of axolotl class II molecules occurs independently of thyroxin.
Unlike most salamanders, the Mexican axolotl (Ambystoma mexicanum) fails to produce enough thyroxin to undergo anatomical metamorphosis, although a "cryptic metamorphosis" involving a change from fetal to adult hemoglobins has been described. To understand to what extent the development of the axolotl hemopoietic system is linked to anatomical metamorphosis, we examined the appearance and thyroxin dependence of class II molecules on thymus, blood, and spleen cells, using both flow cytometry and biosynthetic labeling followed by immunoprecipitation. Class II molecules are present on B cells as early as 7 weeks after hatching, the first time analyzed. At this time, most thymocytes, all T cells, and all erythrocytes lack class II molecules, but first thymocytes at 17 weeks, then T cells at 22 weeks, and finally erythrocytes at 26-27 weeks virtually all bear class II molecules. Class II molecules and adult hemoglobin appear at roughly the same time in erythrocytes. These data are most easily explained by populations of class II-negative cells being replaced by populations of class II-positive cells, and they show that the hemopoietic system matures at a variety of times unrelated to the increase of thyroxin that drives anatomical metamorphosis. We found that administration of thyroxin during axolotl ontogeny does not accelerate or otherwise affect the acquisition of class II molecules, nor does administration of drugs that inhibit thyroxin (sodium perchlorate, thiourea, methimazole, and 1-methyl imidazole) retard or abolish this acquisition, suggesting that the programs for anatomical metamorphosis and some aspects of hemopoietic development are entirely separate.
Völk
H
H
Basel Institute for Immunology, CH-4005 Basel, Switzerland.
Charlemagne
J
J
Tournefier
A
A
Ferrone
S
S
Jost
R
R
Parisot
R
R
Kaufman
J
J
D000557:Ambystoma / Q000196:embryology / Q000254:growth & development / Q000276:immunology* / Q000378:metabolism; D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D001772:Blood Cell Count; D003080:Cold Temperature; D004912:Erythrocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D005434:Flow Cytometry; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects*; D005914:Globins / Q000032:analysis; D000949:Histocompatibility Antigens Class II / Q000032:analysis* / Q000097:blood / Q000276:immunology; D007136:Immunoglobulins / Q000032:analysis / Q000097:blood; D008675:Metamorphosis, Biological / Q000187:drug effects; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013950:Thymus Gland / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013974:Thyroxine / Q000494:pharmacology*
D000949:Histocompatibility Antigens Class II; D007136:Immunoglobulins; D005914:Globins; D013974:Thyroxine